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Background: This study sought to correlate faecal and urinary N-methylhistamine (NMH) concentrations with resting
versus degranulated duodenal mast cell numbers in dogs with chronic enteropathies (CE), and investigate correlations
between intestinal mast cell activation and clinical severity of disease as assessed by canine chronic enteropathy clinical
activity index (CCECAI), and between urinary and faecal NMH concentrations, mast cell numbers, and histopathological
scores. Twenty-eight dogs with CE were included. Duodenal biopsies were stained with haematoxylin and eosin
(H&E), toluidine blue, and by immunohistochemical labelling for tryptase. Duodenal biopsies were assigned a
histopathological severity score, and duodenal mast cell numbers were counted in five high-power fields after
metachromatic and immunohistochemical staining. Faecal and urinary NMH concentrations were measured by
gas chromatography–mass spectrometry.
Results: There was no correlation between the CCECAI and faecal or urinary NMH concentrations, mast cell numbers,
or histopathological score – or between faecal or urinary NMH concentration and mast cell numbers. Post hoc analysis
revealed a statistically significant difference in toluidine blue positive mast cells between two treatment groups (exclusion
diet with/without metronidazole versus immunosuppression (IS)), with higher numbers among dogs not requiring IS.
Conclusion: Faecal and urinary NMH concentrations and duodenal mast cell numbers were not useful indicators of
severity of disease as assessed by the CCECAI or histological evaluation. The number of duodenal mast cells was higher
in dogs that did not need IS, i.e. in dogs responding to an exclusion diet (with/without metronidazole), than in dogs
requiring IS. Further studies comparing the role of mast cells in dogs with different forms of CE are needed.
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Canine chronic enteropathies (CE) are characterised by
inflammatory cell infiltration of the intestinal lamina
propria, the most common of which is lymphoplasmacytic
[1,2]. This condition can retrospectively be classified into
food-responsive disease (FRD), antibiotic-responsive dis-
ease (ARD), and idiopathic inflammatory bowel disease* Correspondence: kristin.anfinsen@nmbu.no
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unless otherwise stated.(IBD) according to response to treatment [1,3,4]. Clinical
markers of disease are sparse to date; few parameters have
been found to predict the need for immunosuppression
(IS) versus diet or antimicrobial treatment alone, or to
predict refractoriness to treatment and hence prognosis
[2,5].
Aberrant immune responses against antigens such as
the intestinal microbiota or food allergens in the intestinal
lumen are thought to play a role in the development of
canine CE [3,6,7]. These aberrant responses may in part
be attributable to a type I hypersensitivity reaction, which
involves degranulation of mast cells in the intestinal
mucosa [8]. Moreover, mast cells have been suggestedal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Anfinsen et al. Acta Veterinaria Scandinavica  (2014) 56:952 Page 2 of 9to play a role in the pathogenesis of canine and human
enteropathies and may be a marker of disease severity
[8-12]. Studies investigating numbers of mast cells in
human IBD (i.e. Crohn’s disease (CD) and ulcerative colitis
(UC)) have found conflicting results [13-16]; possibly
reflecting the importance of mast cell activation rather
than absolute numbers in the mucosa [12].
German and colleagues investigated leukocyte subsets
in the canine intestine based on biopsies obtained from
10 dogs of various breeds with no known enteropathies,
providing a reference for future studies on mast cell
numbers in the canine intestinal mucosa [17]. A few
years later, the same investigators reported leukocyte
subsets in the duodenal mucosa of 27 dogs with chronic
gastrointestinal disease [18]. In the latter study, a lower
number of mast cells was detected in 9 dogs with idio-
pathic IBD (excluding FRD and ARD) compared to 11
dogs with ARD and 23 healthy controls. This was in
contrast to Locher et al. [9], who reported a higher
number of mast cells in the stomach and duodenum in
20 dogs with IBD compared to 9 healthy controls.
Mast cells are bone marrow-derived cells reaching
maturity within the tissues, with characteristic meta-
chromatically staining granules containing inflammatory
mediators such as heparin and histamine [19]. Cross-
linking of IgE molecules on the surface of mast cells
leads to degranulation and release of the inflammatory
mediators, evoking inflammatory changes. Once mast
cells have released their granules, their ability to stain in
a metachromatic fashion diminishes. The metachromatic
properties of mast cell granules are attributed to heparin,
accounting for the difficulties identifying mast cells that
have released the contents of their granules. However,
monoclonal antibodies for tryptase and chymase are able
to identify small amounts of these mast cell-specific
proteases, providing a method for detecting even degra-
nulated (i.e. activated) mast cells [12]. The content of
tryptase versus chymase in mast cells varies between
tissue localisation [20]. In the human and canine gastro-
intestinal tract, mast cells that only contain tryptase
(MCT) have been shown to outnumber cells containing
both tryptase and chymase (MCTC), or cells only contain-
ing chymase (MCC) [9,10,20,21]. These findings suggest
that monoclonal antibodies for tryptase most accurately
identify activated intestinal mast cells.
As the quantification of intestinal mast cell numbers is
difficult, serum markers for the detection of mediators
released from mast cells have been described. Histamine
is one of the major inflammatory mediators released
from activated mast cells, and histamine concentrations
may directly reflect the degree of mast cell activation
[22]. However, histamine in serum is rapidly metabolised
to form N-methylhistamine (NMH) and imidazole acetal-
dehyde [23]. Due to the short half-life of serum histamine[24], measurement of metabolites in body excretions (urine
and faeces) is considered to more accurately reflect the
overall mast cell activity [23]. Moreover, NMH is an easily
measurable parameter that can be analysed in specimens
obtained by non-invasive means, i.e., in faeces or voided
urine [25]. A gas chromatography–mass spectrometry
(GC-MS) method for measurement of NMH concentra-
tions in canine urine samples and faecal extracts has
recently been validated [25]. There is increasing evidence
that NMH concentration is elevated in the urine and
faeces of some dogs with gastrointestinal disease, such as
racing sled dogs with gastro-intestinal ulcerations [26],
Lundehunds with protein-losing enteropathy [27], and in
dogs with CE [28]. Further, it has been shown that NMH
concentrations are increased in plasma and urine of
humans with IBD – with higher concentrations associ-
ated with a higher clinical activity index, and decreasing
concentrations corresponding to clinical remission follow-
ing therapy [29,30]. Only one study has so far investigated
a possible correlation between severity of clinical disease
and histamine concentrations in canine CE [28]. An
increase in faecal NMH was found in dogs with chronic
gastrointestinal disease compared to healthy controls, and
one quarter of the dogs with CE had increased urinary
NMH. However, concentrations did not correlate with
severity of disease as assessed by the canine chronic
enteropathy clinical activity index (CCECAI) [5].
The aim of the present study was to correlate faecal and
urinary NMH concentrations with resting (i.e., metachro-
matically staining) versus degranulated (i.e., identified
by monoclonal tryptase antibodies) duodenal mast cell
numbers, hypothesising that urinary and/or faecal NMH
concentrations would increase with increasing mast cell
degranulation and hence serve as markers for mast cell
activity. We further sought to investigate possible correla-
tions between mast cell activation (assessed by degranula-
tion and NMH concentrations) and clinical disease activity
index (CCECAI), hypothesising that we would find evi-
dence of increased mast cell activity in patients with
clinically more severe disease. Finally, we investigated
the relationship between both NMH concentrations
and mast cell numbers versus histopathological scores, the
latter assessed according to the standards defined by the
World Small Animal Veterinary Association (WSAVA)
Gastrointestinal Standardization Group [31].
Materials and methods
Selection of cases
The archived serum and histology samples for this study
have been taken for diagnostic purposes only and are
residual samples already stored and available in the Royal
Veterinary College (RVC) archive. They were originally
obtained with informed owner consent under the Veterin-
ary Surgeons Act (residual clause) and approved by the
Figure 1 Duodenal section from a dog with chronic enteropathy
stained with toluidine blue for metachromatic staining of mast
cells (×200). Purple cells represent mast cells. Bar = 100 μm.
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gations Centre at the RVC has archived samples from dogs
with CE since 2005; consisting of serum, plasma, urine, fae-
ces, gastrointestinal biopsies, or any combination thereof.
An identification number labels all samples, allowing retro-
spective review of clinical data from the Queen Mother
Hospital for Animals’ electronic and/or paper records. The
enteropathy archive was searched for dogs with a final diag-
nosis of CE for which urine, faeces, duodenal biopsies, and
clinical data were available. Previously reported groups of
clinically healthy dogs were used as controls for establishing
control ranges for urinary and faecal NMH concentrations
(n = 6 and n = 49, respectively) [25,28].
Clinical diagnosis and laboratory methods
All dogs selected for the study had presented to the
Queen Mother Hospital for Animals (QMHA) with a
chronic (3 weeks or more) history of vomiting and/or
diarrhoea. Exclusion of extra gastrointestinal disease as a
cause of the presenting signs was based on results from
routine blood work (haematology and serum biochemistry),
urinalysis, faecal parasitology, endocrine tests (basal cortisol
or ACTH stimulation test), serum trypsine-like immunore-
activity, and abdominal ultrasound examination. Gastro-
duodenoscopy was performed in all dogs, and duodenal
biopsies were fixed in phosphate-buffered formalin solution
followed by paraffin embedding. Clinical disease activity
index (expressed as CCECAI) was assigned to each dog at
the time of presentation (n = 6) or retrospectively by review
of paper and electronic records (n = 22) by one of the inves-
tigators (KPA) [5]. All clients seen at the QMHA are asked
questions based on a standardised questionnaire, facilitating
retrospective determination of the CCECAI. Treatments
were initiated stepwise according to clinician preference at
the time, and were recorded as exclusion diet (i.e. novel or
hydrolysed protein diet fed exclusively), antimicrobial ther-
apy (metronidazole), and/or immunosuppressive therapy
(prednisolone, azathioprine, and/or cyclosporine).
Duodenal biopsies were stained with haematoxylin and
eosin (H&E) for routine histopathological evaluation – all
of which were examined by board-certified pathologists at
the time of the initial investigation. A single board-certified
pathologist (SP), blinded to all other information about the
dogs, reassessed the duodenal biopsies to provide a histo-
pathological score according to the standards set by the
WSAVA Gastrointestinal Standardization Group [31].
Metachromatic staining with toluidine blue was per-
formed as described elsewhere [12] (Figure 1). Immunohis-
tochemical staining for mast cell tryptase was performed
using an automated staining machine (Leica BondMax)
and amplification kit (Leica Refine), according to the
standard immunohistochemical protocol used at the
RVC Diagnostic Laboratory (Figure 2). Briefly, 4 μm
sections of duodenal mucosa were pretreated with apH 9.0 retrieval solution (Dako Epitope Retrieval 2 solu-
tion, Dako, Ely) for 10 minutes then a mouse anti-human
mast cell tryptase monoclonal antibody (Dako) was used
at a 1:800 dilution. Sections were counterstained with
haematoxylin.
Numbers of mucosal mast cells were assessed in duo-
denal biopsies by metachromatic staining (toluidine blue;
MCTB) and by immunohistochemical labelling for tryptase
(MCT) [21]. Duodenal mast cell numbers were counted in
five high-power fields (×40) for each dog and each staining
method by one of the authors (KPA).
Faecal and urine samples (either voided or collected
by cystocentesis) from all dogs were frozen at −80°C, for
up to 2.5 years, until further analysis. Faecal and urinary
NMH concentrations were determined by GC-MS as
described elsewhere [25,32]. The assay has previously
been analytically validated for use in dogs at the Texas
A&M Gastroenterology Laboratory [25].Statistical analyses
Spearman’s rank correlation coefficient was calculated
to assess correlation between faecal and urinary NMH
concentrations with clinical severity of disease (expressed
as CCECAI) and histological severity of disease (expressed
as WSAVA score), and between mast cell numbers and
clinical and histological severity of disease. Normality
was assessed by the Shapiro Wilk test. For non-normally
distributed data, Mann–Whitney U test was used for com-
parison of mast cell numbers and NMH concentrations
between treatment groups (diet and/or antimicrobials
versus immunosuppressive treatment). T-test was used
for normally distributed data. Statistical significance level
was set at P < 0.05.
Figure 2 Duodenal section from a dog with chronic enteropathy
labelled immunohistochemically with anti-human mast cell
tryptase (×200). Brown cells represent mast cells. Bar = 100 μm.
Anfinsen et al. Acta Veterinaria Scandinavica  (2014) 56:952 Page 4 of 9Results
Between November 2005 and August 2011, samples from
259 dogs with a recorded diagnosis consistent with CE
(e.g. IBD, enteropathy, protein-losing enteropathy, food-
responsive enteropathy, gastroenteritis) were archived.
For 32 of these dogs, urine, faeces, and duodenal biopsy
samples were recorded to be available. Retrospective
review of records from these dogs led to exclusion of
one dog due to a final diagnosis of histiocytic ulcerative
colitis. Another 3 dogs were excluded due to concurrent
severe extra-intestinal disease, with potentially overlapping
clinical signs (renal lymphoma, hepatic lymphoma, and
immune-mediated haemolytic anaemia). The final study
population consisted of 28 dogs, 21 of which had all
samples (duodenal biopsies, urine and faeces) present in
the archive. (Duodenal and faecal samples were available
from 24 dogs each; from 1 dog both faecal and duodenal
samples were missing).
Median age of the dogs in the study population was
4 years (range: 13 months-10 years); 13 females (10
spayed) and 15 males (9 castrated). Eight breeds were
represented, including 8 Labrador retrievers, 3 German
shepherd dogs, 2 Cocker spaniels, 2 Cross breed dogs,
and one each of: Cavalier King Charles spaniel, Siberian
Husky, Keeshond, Staffordshire Bull terrier, Jack Russell
terrier, Yorkshire terrier, Greyhound, Newfoundland,
Weimaraner, Utagon, Dogue de Bordeaux, Golden retriever,
and Miniature schnauzer.
Median urinary NMH concentration was 97 ng/mg
creatinine (range 5–249 ng/mg creatinine), and median
faecal NMH concentration was 48 ng/g (range 0–
1,451 ng/g) (Table 1). These concentrations were within
the normal range (0–136 ng/mg creatinine for urinary
NMH and 0–191 ng/g for faecal NMH) [25,28], and not
significantly different from the 3-day mean faecal NMHconcentrations previously reported in 49 healthy control
dogs (53 ng/g, range 9–252 ng/g) [28]. Six dogs had
urinary NMH concentrations above the upper limit of the
reference interval, and 4 dogs had faecal NMH higher
than the upper limit of the reference interval; 2 dogs had
both urinary and faecal NMH concentrations above the
upper limit of the reference interval. Median CCECAI was
6 (range 2–13), and median histopathology score 2 (range
0–9). In 2 dogs (with histopathology scores of 0 and 4),
the duodenal biopsies were of inadequate quality as
defined by the WSAVA Gastrointestinal Standardization
group, and these biopsies were excluded from further
analyses of histopathological severity.
There was no correlation between the CCECAI and
faecal or urinary NMH concentrations (Spearman’s rho
0.23 and −0.032, respectively), mast cell numbers (MCTB
or MCT; rho −0.004 and 0.04, respectively), or histopath-
ology score (rho −0.103). Furthermore, there was no
correlation between faecal (rho 0.05 and −0.001 for MCTB
and MCT, respectively) or urinary (rho 0.18 and 0.26 for
MCTB and MCT, respectively) NMH concentration and
mast cell numbers, nor was there any correlation between
urinary and faecal NMH concentrations (rho 0.22).
Treatment initiated or advised by clinicians at the
QMHA was recorded for each dog, and consisted of an
exclusion diet with (n = 9) or without (n = 9) metronida-
zole, or IS (n = 10; these dogs had failed treatment trials
with diet and metronidazole, either prior to or after refer-
ral to the QMHA). Biopsies from 4 of the dogs (3 treated
with IS, one with diet and metronidazole) were missing
from the archive. Due to the low number of dogs, assess-
ment of differences between treatment groups was not
attempted in this study. However, the data gave an
impression of higher numbers of mast cells detected in
duodenal biopsies from dogs in which IS therapy was not
necessary; i.e. dogs responding to an exclusion diet with
or without metronidazole. Post hoc analysis revealed that
dogs eventually requiring immunosuppressive therapy had
less MCTB (P = 0.041) in their pre-treatment biopsies than
those responding to an exclusion diet, with or without
metronidazole, (Figure 3). There was no statistically sig-
nificant difference between these groups for numbers of
MCT (P = 0.105; Figure 4), and there was no difference
between numbers of MCTB in dogs treated with an exclu-
sion diet and metronidazole versus an exclusion diet alone
(P = 0.41; Figure 5). Faecal and urinary NMH concentra-
tions did not differ between treatment groups (P = 0.52
and P = 0.95, respectively).
Discussion
We were unable to find a correlation between intestinal
mast cell numbers and clinical severity of disease as
assessed by CCECAI based on the dogs enrolled in this
study. Previous studies assessing mast cell numbers in
Table 1 Summary of clinical and clinicopathological data in 28 dogs with chronic enteropathy
Dog Age
(years)
Sex CCECAI Therapy Fecal NMH Urinary NMH Mast cells (mean
number/10 hpf)
Histopathology
duodenum
≤191(ng/g) ≤136(ng/mg creatinine) TB IHC WSAVA score Infiltrate
1 9y 4 m FN 12 D, IS 74 176 16.6 31.4 3 LP
2 1y 5 m MN 6 D, M - 46 3.2 21 0 N/A
3 3y 8 m MN 5 D, M 40 86 22.6 22.6 1 LP
4 2y 1 m F 7 D, M 0 32 2 16 1 neut
5 1y 3 m M 5 D - 474 1.4 10 0 N/A
6 10y MN 9 D, M - 69 11.6 16.4 3 LP
7 1y 6 m FN 6 D, IS 165 108 1.2 2.6 0 N/A
8 7y 9 m FN 7 D, M, IS 789 186 2.6 13.4 2 -
9 5y 8 m MN 9 D 57 132 9.2 28 0 N/A
10 3y 1 m MN 3 D, M 139 95 10 11.8 1 -
11 6y 5 m MN 4 D 1451 62 6.4 10.2 5 LP, eos
12 2y 7 m MN 6 D, M 0 249 8 27.4 5 eos
13 4y 11 m FN 7 D, IS 54 112 2.2 2 1 -
14 8y M 13 D, M 272 114 3.8 9.8 4 LP
15 2y 6 m M 7 D, M 98 68 1.6 12.2 5 LP*
16 4y F 8 D, IS 1150 163 0.2 8.6 5 eos
17 4y 4 m M 9 D, IS 29 19 1 4.2 1 -
18 3y 10 m FN 6 D 0 53 0.4 7.8 2 LP
19 1y 1 m MN 5 D 0 100 8.8 4.2 9 LP, eos**
20 1y 2 m MN 5 D 0 99 3.6 9.2 1 -
21 6y 2 m FN 9 D, IS 0 43 0.1 1.2 3 LP
22 3y 3 m FN 2 D 0 46 0.4 2.2 3 LP*
23 6y 6 m M 6 D 131 53 2.8 10.4 6 LP
24 8y 2 m FN 9 D 105 5 9.2 6.6 0 N/A
25 4y 5 m M 11 D, IS 41 76 - - - -
26 1y 1 m F 6 D, M, IS - 52 - - - -
27 8y 7 m FN 4 IS 0 116 - - - -
28 4y FN 6 D, M 38 151 - - - -
Median 6 47.5 90.5 3 10.1 2
Min 2 0 5 0.1 1.2 0
Max 13 1451 474 22.6 31.4 9
CCECAI, canine chronic enteropathy clinical activity index; NMH, N-methylhistamine; hpf, high-power field; TB, toluidine blue; IHC, immunohistochemistry (tryptase); WSAVA,
World Small Animal Veterinary Association; FN, female neutered; MN, male neutered; D, diet (novel or hydrolysed protein); M, metronidazole; IS, immunosuppressive drug
(prednisolone, azathioprine, cyclosporine); LP, lymphoplasmacytic; neut, neutrophilic; eos, eosinophilic; *, moderate; **, marked; N/A, not applicable; − data missing.
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results, which may be partially explained by differences
in fixation and/or staining techniques [3,33]. More spe-
cifically, it has been postulated that mast cell degranula-
tion with release of inflammatory mediators could
explain a decrease in detectable mast cells in diseased
tissue, as degranulated mast cells stain poorly [3,12].
Immunolabelling for mast cell proteases (i.e. tryptase
and/or chymase) enables identification of degranulated
cells. A decrease in metachromatically staining mastcells in combination with a constant to increasing num-
ber of tryptase positive mast cells in patients with
inflammatory intestinal disease would support a role of
mast cell mediators in that particular patient. Therefore,
we investigated the number of both metachromatically
staining mast cells (MCTB) and of MCT. The lack of
correlation between either of these and CCECAI could
suggest that mast cells and mast cell mediators are not
major contributors to the clinical signs observed in
canine patients with CE.
Figure 3 Median numbers of MCTB in 5 high power fields (×40)
for 24 dogs with chronic enteropathy, grouped based on
treatment. IS = treated by immunosuppression; Metr = treated with
metronidazole. Lines represent median and interquartile range.
Figure 5 Median numbers of MCTB in 5 high power fields (×40)
for 24 dogs with chronic enteropathy, separated by treatment
group. IS = treated by immunosuppression; Metr = treated with
metronidazole. Lines represent median and interquartile range.
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human patients with IBD (i.e. CD and UC) have also
reported conflicting results. Dvorak et al. [13] identified
mast cells by electron microscopy and found increased
numbers of mast cells in the ileal mucosa of patients
with CD compared to healthy controls. Nishida et al.
[15] utilised immunohistochemical staining for tryptase
and described higher mast cell numbers in patients with
both CD and UC than in healthy controls. In contrast,
Nolte et al. [34] reported increased numbers of mastFigure 4 Median numbers of MCT in 5 high power fields (×40)
for 24 dogs with chronic enteropathy, grouped based on
treatment. IS = treated by immunosuppression; Metr = treated with
metronidazole. Lines represent median and interquartile range.cells in patients with UC, but similar numbers in those
with CD, when comparing metachromatically staining
mast cells in humans with IBD to healthy controls. Mast
cell numbers were higher in inflamed tissue than normal
tissue from both patient groups. Balász et al. [14] also
reported higher numbers of metachromatically staining
mast cells in patients with active UC than in patients in
remission. In contrast, King et al. [16] found a decreased
number of mast cells in areas of active inflammation in
patients with UC compared to normal colonic mucosa
from the same individuals.
The discrepancies in both human and canine studies
may partially be explained by different staining tech-
niques, resulting in a variable ability to identify intact
versus degranulated mast cells [35]. More specifically,
mast cell degranulation could explain why German et al.
[18] found decreased numbers of mast cells identified by
toluidine blue in dogs with IBD, whereas Locher et al.
showed numbers of duodenal tryptase positive mast cells
to be increased in dogs with this condition [3,9]. Bearing
this in mind, Kleinschmidt et al. [10] sought to identify
the number of metachromatically staining mast cells
(using kresylecht-violet; MCKEV) versus tryptase and/or
chymase positive mast cells (MCtotal) in dogs with inflam-
matory enteropathies versus controls. Although their find-
ings generally showed a decrease in mast cell numbers in
diseased dogs, they identified higher numbers of MCtotal
versus MCKEV in 14 of 19 small intestinal samples from
inflamed areas in affected dogs, whereas this was the case
for only 8 of 20 unaffected areas of the small intestine
from these patients, suggesting an association between
mast cell activation and intestinal inflammation in this
population of dogs.
Post hoc analysis of the data in this study revealed higher
numbers of MCTB in dogs treated with an exclusion diet
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requiring IS to control clinical signs (P = 0.041), supporting
a role of mast cell infiltration and activation in this subset
of dogs with CE. The low number of cases can most likely
explain the lack of a statistically significant difference be-
tween numbers of MCT. However, it could also suggest
increased mast cell activation (leading to lower numbers of
MCTB, but not MCT) in dogs requiring IS. Interestingly,
German et al. reported similar findings in 27 dogs with CE
[18]. Dogs classified as having IBD (i.e. requiring IS) had
significantly lower numbers of MCTB than dogs with ARD,
and dogs with FRD appeared to have similar numbers of
MCTB as the dogs with ARD; lack of a significant difference
between dogs in the dogs with FRD and IBD in our study
could be due to a low number of dogs with FRD (n = 6).
Lower amounts of IgE antibodies detected in the faeces of
Soft Coated Wheaten Terriers fed an exclusion diet, and
peak faecal IgE levels measured following feeding with a
provocative diet, lends some support to the theory that
mast cell activation may be involved in the pathogenesis
of FRD [36].
Using similar techniques as the present study for
metachromatic staining (toluidine blue) and counting of
duodenal mucosal mast cell numbers, Berghoff et al. [28]
reported a median mast cell count of 4.4 per high-power
field (range 0–17, n = 11) in dogs with CE. These numbers
are similar to ours, and in line with our findings, the degree
of mast cell infiltration did not correlate with the urinary or
faecal NMH. Their study did not include information about
treatment, precluding any such comparisons.
In accordance with previous studies, we did not find
any correlation between CCECAI and the histopathological
score – underlining the need for additional markers of clin-
ical disease and response to treatment [37,38]. In human
patients with IBD (CD or UC), urinary NMH has been
correlated to clinical disease activity and severity of lesions
observed by endoscopy, with increased urinary NMH con-
centrations corresponding to active disease, and urinary
NMH concentrations during clinical remission being simi-
lar to those of healthy controls [29,30]. In our study, neither
urinary nor faecal concentrations of NMH correlated with
clinical disease activity (CCECAI), and in contrary to mast
cell numbers, there was no difference in urinary or faecal
NMH concentrations between treatment groups. This
could again reflect low numbers of cases. Moreover, it is
likely that mast cell activation and release of histamine play
a role only in a subgroup of dogs, further decreasing the
power of our study, as we included dogs with ARD, FRD,
and IBD. Finally, we cannot exclude inaccurate results due
to decay of urinary and faecal NMH during storage,
although there was no indication of lower values found in
the older compared to the newer samples (data not shown).
Previous studies have suggested a role of histamine
release in select groups of dogs with enteropathy. Vadenet al. [39] reported decreased release of histamine from
jejunal mast cells following in vitro stimulation of biopsies
from Soft Coated Wheaten Terriers with protein-losing
enteropathy and/or –nephropathy, and postulated that
this could reflect depletion of histamine due to ongoing
degranulation. Berghoff et al. [27] found increased faecal
NMH concentrations in Norwegian Lundehunds with
chronic gastrointestinal disease compared to healthy
controls and also in racing Alaskan sled-dogs, prone to
gastrointestinal ulceration, compared to working Retrievers
[26]. These findings were followed up by the first study
investigating a potential correlation between faecal and
urinary NMH concentrations and clinical severity of
disease in dogs with CE [28]. In line with our findings,
there was no correlation between faecal and urinary
NMH, or between either faecal or urinary NMH concentra-
tions and the CCECAI scores. However, dogs with CE had
higher mean concentrations of faecal NMH than healthy
control dogs, and 4/16 dogs had increased urinary and
faecal NMH concentrations (only 1 dog had an increase in
both). The authors suggested that histamine release was
likely to play a role in some dogs with CE. Interestingly, the
4 dogs with increased urinary NMH concentrations all had
moderate inflammatory infiltrate in the duodenal mucosa,
whereas the inflammatory changes in the 12 dogs with
normal urinary NMH were moderate in one and mild in
the remaining dogs. These findings contrast ours, as none
of the dogs with moderate or marked duodenal mucosal
inflammation (dog number 15, 19, 22) had increased
urinary NMH. This discrepancy could be due to the
low number of cases in both studies, and in particular, the
generally mild histopathological changes in our population.
The proportion of dogs with increased faecal or urinary
NMH in our study (17 and 21%, respectively) was compar-
able to the 25% reported by Berghoff et al. [28].
In our study, incorporating a histopathology score and
mast cell numbers unfortunately did not help to eluci-
date the potential clinical utility of measuring NMH, as
neither faecal nor urinary NMH concentrations correlated
with mast cell numbers or histopathological severity.
However, it did lend some support to mast cell infiltration
playing a role in a subgroup of dogs with CE – revealing a
higher number of mast cells by metachromatic staining
(MCTB) in dogs with FRD and ARD. As there was no
significant difference in numbers of MCT, increased
degranulation in dogs with IBD could not be ruled out,
but this finding was thought to more likely be due to
low numbers and hence lack of power to detect a differ-
ence in this group.
Another limitation of this study, was that only endo-
scopically obtained duodenal biopsies were available. It is
possible that a correlation between NMH concentrations
and clinical severity (CCECAI) or mast cell numbers could
have been detected if jejunal, ileal and/or full-thickness
Anfinsen et al. Acta Veterinaria Scandinavica  (2014) 56:952 Page 8 of 9biopsies had been available for analyses. Recent studies have
shown histological discrepancies between duodenal and
ileal samples from dogs with CE, and indicated a higher
frequency of ileal versus duodenal lesions – although the
number of mast cells were not assessed in these studies
[38,40]. Kleinschmidt et al. [10] utilised full-thickness
biopsies from all segments of the canine gastrointestinal
tract to assess intestinal mast cell numbers and distribution.
These investigators described lower mast cell numbers in
the submucosa than the lamina propria, rendering the ab-
sence of deeper layers (i.e. the submucosa and muscularis)
in the biopsies an unlikely cause of our negative findings.
However, in dogs with lymphoplasmacytic enteritis, lower
numbers of MCT were reported in the duodenum and
jejunum compared to the ileum. Including assessment of
ileal biopsies would have strengthened the present study,
but was not feasible due to its retrospective nature.
Conclusions
Our study did not show any correlations between urinary
or faecal NMH concentrations and clinical disease severity
or numbers of intestinal mast cells. However, there was a
trend of increased numbers of intestinal mast cells in dogs
responding to diet and/or antimicrobial therapy compared
to those requiring IS. Further studies designed to look at
differences in intestinal mast cells between dogs with
the three major forms of CE (FRD, ARD, and idiopathic
IBD) are required to investigate the significance of this
observation.
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